Der p 3; diagnosis; hypoallergen; inactive enzyme; recombinant mite allergen; specific immunotherapy
Abstract :
[en] BACKGROUND: The allergen Der p 3 is underrepresented in house dust mite (HDM) extracts probably due to autolysis. Recombinant stable molecule of the allergen is thus needed to improve the diagnosis of allergy and the safety and efficacy of immunotherapy. OBJECTIVE: The current study reports the immunological characterization of two recombinant molecules of the HDM allergen Der p 3 as useful tools for diagnosis and immunotherapy. METHODS: Recombinant mature (rDer p 3) and immature (proDer p 3) Der p 3 and their corresponding S196A mutants were produced in Pichia pastoris and purified. The stability, IgE-binding capacity and allergenicity of the different proteins were analyzed and compared with those of the major mite allergen Der p 1 used as a reference. Additionally, the immunogenicity of the different allergens was evaluated in a murine model of Der p 3 sensitization. RESULTS: Compared to the IgE reactivity to recombinant and natural Der p 3 (nDer p 3), the mean IgE binding of patient's sera to rDer p 3-S196A (50 %) was higher. The poorly binding to nDer p 3 or rDer p 3 was due to autolysis of the allergen. Contrary to Der p 3, proDer p 3 displayed very weak IgE reactivity, as measured by sandwich ELISA and competitive inhibition, RBL degranulation and human basophil activation assays. Moreover, proDer p 3 induced a TH 1-biased immune response that prevented an allergic response in mice but retained Der p 3-specific T cell reactivity. CONCLUSION: rDer p 3-S196A should be used for the diagnosis of HDM allergy elicited by Der p 3, and proDer p 3 may represent a hypoallergen of Der p 3. This article is protected by copyright. All rights reserved.
Research center :
CIP - Centre d'Ingénierie des Protéines - ULiège
Disciplines :
Immunology & infectious disease
Author, co-author :
Bouaziz, Ahlem ; Université de Liège > Département des sciences de la vie > Centre d'ingénierie des protéines
Walgraffe, David
Bouillot, Celine
Herman, Julie
FOGUENNE, Jacques ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie biologique et immuno hématologie
Gothot, André ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Biologie de la coagulation et de l'hémostase
Louis, Renaud ; Université de Liège - ULiège > Département des sciences cliniques > Pneumologie - Allergologie
Hentges, Francois
Jacquet, Alain
Mailleux, Anne-Catherine
Chevigne, Andy
Galleni, Moreno ; Université de Liège - ULiège > Département des sciences de la vie > Macromolécules biologiques
Development of recombinant stable house dust mite allergen Der p 3 molecules for component-resolved diagnosis and specific immunotherapy.
Publication date :
2015
Journal title :
Clinical and Experimental Allergy
ISSN :
0954-7894
eISSN :
1365-2222
Publisher :
Blackwell, Oxford, United Kingdom
Volume :
45
Peer reviewed :
Peer Reviewed verified by ORBi
Name of the research project :
Mise au point d’une forme stable de l’allergène Der p 3 de Dermatophagoides pteronyssinus pour le diagnostic rapide et le développement de nouvelles approches d’immunothérapie de l’allergie aux acariens
Funders :
ULiège - Université de Liège [BE]
Commentary :
This article is protected by copyright. All rights reserved.
Bousquet PJ, Chinn S, Janson C, Kogevinas M, Burney P, Jarvis D. Geographical variation in the prevalence of positive skin tests to environmental aeroallergens in the European Community Respiratory Health Survey I. Allergy 2007; 62:301-9.
Gaffin JM, Phipatanakul W. The role of indoor allergens in the development of asthma. Curr Opin Allergy Clin Immunol 2009; 9:128-35.
Thomas WR. Geography of house dust mite allergens. Asian Pac J Allergy Immunol 2010; 28:211-24.
Moingeon P, Mascarell L. Novel routes for allergen immunotherapy: safety, efficacy and mode of action. Immunotherapy 2012; 4:201-12.
Cox L, Nelson H, Lockey R et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol 2011; 127(1 Suppl):S1-55.
Chapman MD, Ferreira F, Villalba M et al. The European Union CREATE project: a model for international standardization of allergy diagnostics and vaccines. J Allergy Clin Immunol 2008; 122:882-9 e2.
van Ree R, Chapman MD, Ferreira F et al. The CREATE project: development of certified reference materials for allergenic products and validation of methods for their quantification. Allergy 2008; 63:310-26.
Filep S, Tsay A, Vailes L et al. A multi-allergen standard for the calibration of immunoassays: CREATE principles applied to eight purified allergens. Allergy 2012; 67:235-41.
Casset A, Mari A, Purohit A et al. Varying allergen composition and content affects the in vivo allergenic activity of commercial Dermatophagoides pteronyssinus extracts. Int Arch Allergy Immunol 2012; 159:253-62.
Jacquet A. The role of the house dust mite-induced innate immunity in development of allergic response. Int Arch Allergy Immunol 2011; 155:95-105.
Thomas WR. The advent of recombinant allergens and allergen cloning. J Allergy Clin Immunol 2011; 127:855-9.
Bordas-Le Floch V, Bussieres L, Airouche S et al. Expression and characterization of natural-like recombinant Der p 2 for sublingual immunotherapy. Int Arch Allergy Immunol 2012; 158:157-67.
Lucas JM. Microarrays: molecular allergology and nanotechnology for personalised medicine (II). Allergol Immunopathol (Madr) 2010; 38:217-23.
Pauli G, Malling HJ. Allergen-specific immunotherapy with recombinant allergens. Curr Top Microbiol Immunol 2011; 352:43-54.
Valenta R, Niespodziana K, Focke-Tejkl M et al. Recombinant allergens: what does the future hold? J Allergy Clin Immunol 2011; 127:860-4.
Valenta R, Linhart B, Swoboda I, Niederberger V. Recombinant allergens for allergen-specific immunotherapy: 10 years anniversary of immunotherapy with recombinant allergens. Allergy 2011; 66:775-83.
Hales BJ, Martin AC, Pearce LJ et al. IgE and IgG anti-house dust mite specificities in allergic disease. J Allergy Clin Immunol 2006; 118:361-7.
Weghofer M, Thomas WR, Kronqvist M et al. Variability of IgE reactivity profiles among European mite allergic patients. Eur J Clin Invest 2008; 38:959-65.
Shakib F, Ghaemmaghami AM, Sewell HF. The molecular basis of allergenicity. Trends Immunol 2008; 29:633-42.
Jacquet A. Interactions of airway epithelium with protease allergens in the allergic response. Clin Exp Allergy 2011; 41:305-11.
Gregory LG, Lloyd CM. Orchestrating house dust mite-associated allergy in the lung. Trends Immunol 2011; 32:402-11.
King C, Brennan S, Thompson PJ, Stewart GA. Dust mite proteolytic allergens induce cytokine release from cultured airway epithelium. J Immunol 1998; 161:3645-51.
Wan H, Winton HL, Soeller C et al. The transmembrane protein occludin of epithelial tight junctions is a functional target for serine peptidases from faecal pellets of Dermatophagoides pteronyssinus. Clin Exp Allergy 2001; 31:279-94.
Sun G, Stacey MA, Schmidt M, Mori L, Mattoli S. Interaction of mite allergens Der p3 and Der p9 with protease-activated receptor-2 expressed by lung epithelial cells. J Immunol 2001; 167:1014-21.
Adam E, Hansen KK, Astudillo Fernandez O et al. The house dust mite allergen Der p 1, unlike Der p 3, stimulates the expression of interleukin-8 in human airway epithelial cells via a proteinase-activated receptor-2-independent mechanism. J Biol Chem 2006; 281:6910-23.
Stewart GA, Ward LD, Simpson RJ, Thompson PJ. The group III allergen from the house dust mite Dermatophagoides pteronyssinus is a trypsin-like enzyme. Immunology 1992; 75:29-35.
Smith WA, Chua KY, Kuo MC, Rogers BL, Thomas WR. Cloning and sequencing of the Dermatophagoides pteronyssinus group III allergen, Der p III. Clin Exp Allergy 1994; 24:220-8.
Dumez ME, Teller N, Mercier F et al. Activation mechanism of recombinant Der p 3 allergen zymogen: contribution of cysteine protease Der p 1 and effect of propeptide glycosylation. J Biol Chem 2008; 283:30606-17.
Takai T, Kato T, Yasueda H, Okumura K, Ogawa H. Analysis of the structure and allergenicity of recombinant pro- and mature Der p 1 and Der f 1: major conformational IgE epitopes blocked by prodomains. J Allergy Clin Immunol 2005; 115:555-63.
Walgraffe D, Matteotti C, El Bakkoury M et al. A hypoallergenic variant of Der p 1 as a candidate for mite allergy vaccines. J Allergy Clin Immunol 2009; 123:1150-6.
Chevigne A, Barumandzadeh R, Groslambert S et al. Relationship between propeptide pH unfolding and inhibitory ability during ProDer p 1 activation mechanism. J Mol Biol 2007; 374:170-85.
Chevigne A, Dumez ME, Dumoulin M, Matagne A, Jacquet A, Galleni M. Comparative study of mature and zymogen mite cysteine protease stability and pH unfolding. Biochim Biophys Acta 2010; 1800:937-45.
Dumez ME, Herman J, Campisi V et al. The proline-rich motif of the proDer p 3 allergen propeptide is crucial for protease-protease interaction. PLoS ONE 2013; 8:e68014.
Sturm EM, Kranzelbinder B, Heinemann A, Groselj-Strele A, Aberer W, Sturm GJ. CD203c-based basophil activation test in allergy diagnosis: characteristics and differences to CD63 upregulation. Cytometry B Clin Cytom 2010; 78:308-18.
Asturias JA, Ibarrola I, Arilla MC et al. Engineering of major house dust mite allergens Der p 1 and Der p 2 for allergen-specific immunotherapy. Clin Exp Allergy 2009; 39:1088-98.
Nakajima H, Takatsu K. Role of cytokines in allergic airway inflammation. Int Arch Allergy Immunol 2007; 142:265-73.
Schmidlin F, Amadesi S, Dabbagh K et al. Protease-activated receptor 2 mediates eosinophil infiltration and hyperreactivity in allergic inflammation of the airway. J Immunol 2002; 169:5315-21.
Chen CL, Wang SD, Zeng ZY et al. Serine protease inhibitors nafamostat mesilate and gabexate mesilate attenuate allergen-induced airway inflammation and eosinophilia in a murine model of asthma. J Allergy Clin Immunol 2006; 118:105-12.